SCIENCE IN THE NEWS DAILY
Promising Alzheimer's Drug Approved for Late-Stage Trials
from USA Today
An experimental drug for Alzheimer's disease patients showed promise in Phase II clinical trials and is moving into final-stage trials, Wyeth and Elan, the makers of bapineuzumab, announced Tuesday.
Bapineuzumab is designed to fight beta amyloid, a toxic protein that clumps together in the brains of Alzheimer's patients.
In the early studies, conducted around the USA, 240 people with early- to moderate-stage Alzheimer's disease were either assigned bapineuzumab or a placebo. Researchers reported that non-carriers of a gene considered to be a risk factor for Alzheimer's disease, called ApoE4, showed "clinically meaningful benefits" in a battery of tests used to track the progression of Alzheimer's disease.
Read more ...